2024 events that may change the clinical practice for aggressive B-cell lymphomas in the future

The data presented at the 2024 international conferences on the diagnosis and treatment of aggressive B-cell lymphomas were reviewed; 13 striking and important events that could change clinical practice in the future were identified. The presented studies evaluated the efficacy of new therapies for diffuse large B-cell lymphoma in both first-line therapy and relapse settings. The absolute top pick is bispecific antibodies; their efficacy and safety are evaluated in various combinations to develop an optimal strategy for their use at different stages of therapy. There are also two most striking studies on CAR T-cell therapy.